Angiostatin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-00469 |
| CAS | 86090-08-6 |
| Molecular Weight | 278.21 |
| Molecular Formula | C9H14N2O8 |
Online Inquiry
Description
It is produced by the strain of Dihetrospora catenulata SANK 10481, D. chlamidospora SANK 12181, Verticillum viveostratosum SANK 13358. It has the function of inhibiting Angiotensin converting enzyme.
Specification
| Synonyms | ANGIO |
| IUPAC Name | (2-carboxy-2-((carboxymethyl)amino)ethyl)aspartic acid |
Properties
| Appearance | Colorless Acicular Crystal |
| Melting Point | 215-220 °C |
| Solubility | Soluble in Water |
Reference Reading
1. What the structure of angiostatin may tell us about its mechanism of action
J H Geiger, S E Cnudde J Thromb Haemost. 2004 Jan;2(1):23-34. doi: 10.1111/j.1538-7836.2004.00544.x.
Originally discovered in 1994 by Folkman and coworkers, angiostatin was identified through its antitumor effects in mice and later shown to be a potent inhibitor of angiogenesis. An internal fragment of plasminogen, angiostatin consists of kringle domains that are known to be lysine-binding. The crystal structure of angiostatin was the first multikringle domain-containing structure to be published. This review will focus on what is known about the structure of angiostatin and its implications in function from the current literature.
2. Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer's disease
Yuan Cheng, Jun-Rong Ren, Jie-Ming Jian, Chen-Yang He, Man-Yu Xu, Gui-Hua Zeng, Cheng-Rong Tan, Ying-Ying Shen, Wang-Sheng Jin, Dong-Wan Chen, Hui-Yun Li, Xu Yi, Yuan Zhang, Xian-Le Bu, Yan-Jiang Wang Transl Psychiatry. 2022 May 10;12(1):194. doi: 10.1038/s41398-022-01962-6.
Angiostatin, an endogenous angiogenesis inhibitor generated by the proteolytic cleavage of plasminogen, was recently reported to contribute to the development of Alzheimer's disease (AD). However, whether there are pathological changes in angiostatin levels in individuals with AD dementia is unclear, and whether plasma angiostatin has a relationship with major AD pathological processes and cognitive impairment remains unknown. To examine plasma angiostatin levels in patients with AD dementia and investigate the associations of angiostatin with blood and cerebrospinal fluid (CSF) AD biomarkers, we conducted a cross-sectional study including 35 cognitively normal control (CN) subjects and 59 PiB-PET-positive AD dementia patients. We found that plasma angiostatin levels were decreased in AD dementia patients compared to CN subjects. Plasma angiostatin levels were negatively correlated with plasma Aβ42 and Aβ40 levels in AD dementia patients and positively correlated with CSF total tau (t-tau) levels and t-tau/Aβ42 in AD dementia patients with APOE-ε4. In addition, plasma angiostatin levels had the potential to distinguish AD from CN. These findings suggest a link between angiostatin and AD pathogenesis and imply that angiostatin might be a potential diagnostic biomarker for AD.
3. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated
Miriam L Wahl, Daniel J Kenan, Mario Gonzalez-Gronow, Salvatore V Pizzo J Cell Biochem. 2005 Oct 1;96(2):242-61. doi: 10.1002/jcb.20480.
Tumor growth requires the development of new vessels that sprout from pre-existing normal vessels in a process known as "angiogenesis" [Folkman (1971) N Engl J Med 285:1182-1186]. These new vessels arise from local capillaries, arteries, and veins in response to the release of soluble growth factors from the tumor mass, enabling these tumors to grow beyond the diffusion-limited size of approximately 2 mm diameter. Angiostatin, a naturally occurring inhibitor of angiogenesis, was discovered based on its ability to block tumor growth in vivo by inhibiting the formation of new tumor blood vessels [O'Reilly et al. (1994a) Cold Spring Harb Symp Quant Biol 59:471-482]. Angiostatin is a proteolytically derived internal fragment of plasminogen and may contain various members of the five plasminogen "kringle" domains, depending on the exact sites of proteolysis. Different forms of angiostatin have measurably different activities, suggesting that much remains to be elucidated about angiostatin biology. A number of groups have sought to identify the native cell surface binding site(s) for angiostatin, resulting in at least five different binding sites proposed for angiostatin on the surface of endothelial cells (EC). This review will consider the data supporting all of the various reported angiostatin binding sites and will focus particular attention on the angiostatin binding protein identified by our group: F(1)F(O) ATP synthase. There have been several developments in the quest to elucidate the mechanism of action of angiostatin and the regulation of its receptor. The purpose of this review is to describe the highlights of research on the mechanism of action of angiostatin, its' interaction with ATP synthase on the EC surface, modulators of its activity, and issues that should be explored in future research related to angiostatin and other anti-angiogenic agents.
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
